FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016242021> ?p ?o ?g. }

• W2016242021 endingPage "40" @default.
• W2016242021 startingPage "31" @default.
• W2016242021 abstract "The extrahepatic enzyme indoleamine 2,3-dioxygenase (IDO) catalyzes tryptophan degradation in the first and rate-limiting step towards biosynthesis of the central metabolic co-factor nicotinamide adenine dinucleotide (NAD). While this pathway has been known for decades, the actual physiological role for IDO in mammals remained obscure, because (i.) most cell types do not express the downstream enzymes in the NAD biosynthesis pathway and (ii.) mammals salvage rather than synthesize NAD to meet their metabolic needs. An immunological role for IDO was hinted at with the observation that IDO expression is stimulated by interferon-gamma and subsequently confirmed by the discovery of its physiological importance in protecting the fetus from maternal immunity. Similarly, elevations in tryptophan catabolism in cancer patients were known since the 1950s, but the basis and meaning of this phenomenon were uncertain until it was shown that IDO, which is commonly elevated in tumors and draining lymph nodes, suppresses T cell immunity in the tumor microenvironment. Indeed, by creating peripheral tolerance to tumor antigens, IDO can undermine immune responses that thwart tumor cell survival in the context of an underlying inflammatory environment that facilitates tumor outgrowth. In preclinical studies, small molecule inhibitors of IDO compromise this mechanism of immunosuppression and strongly leverage the efficacy of a variety of classical chemotherapeutic agents, supporting the clinical development of IDO inhibitors as a therapeutic goal. This essay summarizes key findings that implicate IDO as an important mediator of peripheral tolerance and discusses the development of anti-cancer modalities that incorporate the use of IDO inhibitors." @default.
• W2016242021 created "2016-06-24" @default.
• W2016242021 creator A5063480688 @default.
• W2016242021 creator A5089381889 @default.
• W2016242021 date "2007-02-01" @default.
• W2016242021 modified "2023-09-23" @default.
• W2016242021 title "Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer" @default.
• W2016242021 cites W1489480103 @default.
• W2016242021 cites W1507706498 @default.
• W2016242021 cites W1554937135 @default.
• W2016242021 cites W1564721318 @default.
• W2016242021 cites W1592933330 @default.
• W2016242021 cites W1598309391 @default.
• W2016242021 cites W1607682771 @default.
• W2016242021 cites W1642873092 @default.
• W2016242021 cites W1942198241 @default.
• W2016242021 cites W1964609124 @default.
• W2016242021 cites W1965769603 @default.
• W2016242021 cites W1967404929 @default.
• W2016242021 cites W1970674279 @default.
• W2016242021 cites W1970841420 @default.
• W2016242021 cites W1972402664 @default.
• W2016242021 cites W1973251492 @default.
• W2016242021 cites W1975510716 @default.
• W2016242021 cites W1975929837 @default.
• W2016242021 cites W1978183014 @default.
• W2016242021 cites W1980841783 @default.
• W2016242021 cites W1984484036 @default.
• W2016242021 cites W1989147967 @default.
• W2016242021 cites W1991987925 @default.
• W2016242021 cites W1992374256 @default.
• W2016242021 cites W1995025647 @default.
• W2016242021 cites W1997582687 @default.
• W2016242021 cites W1998585742 @default.
• W2016242021 cites W2000593166 @default.
• W2016242021 cites W2001717792 @default.
• W2016242021 cites W2009747609 @default.
• W2016242021 cites W2010378562 @default.
• W2016242021 cites W2013729937 @default.
• W2016242021 cites W2014837971 @default.
• W2016242021 cites W2015260577 @default.
• W2016242021 cites W2017717268 @default.
• W2016242021 cites W2017914815 @default.
• W2016242021 cites W2018020394 @default.
• W2016242021 cites W2019214729 @default.
• W2016242021 cites W2021112267 @default.
• W2016242021 cites W2022430924 @default.
• W2016242021 cites W2029383449 @default.
• W2016242021 cites W2030844021 @default.
• W2016242021 cites W2031188680 @default.
• W2016242021 cites W2033520751 @default.
• W2016242021 cites W2036247758 @default.
• W2016242021 cites W2037920661 @default.
• W2016242021 cites W2038163944 @default.
• W2016242021 cites W2042736763 @default.
• W2016242021 cites W2043796257 @default.
• W2016242021 cites W2045293532 @default.
• W2016242021 cites W2045932062 @default.
• W2016242021 cites W2048270768 @default.
• W2016242021 cites W2050793959 @default.
• W2016242021 cites W2052787011 @default.
• W2016242021 cites W205568925 @default.
• W2016242021 cites W2057854239 @default.
• W2016242021 cites W2064718671 @default.
• W2016242021 cites W2066075932 @default.
• W2016242021 cites W2071080970 @default.
• W2016242021 cites W2071982218 @default.
• W2016242021 cites W2073144071 @default.
• W2016242021 cites W2073906172 @default.
• W2016242021 cites W2075262140 @default.
• W2016242021 cites W2077872696 @default.
• W2016242021 cites W2085802461 @default.
• W2016242021 cites W2088828149 @default.
• W2016242021 cites W2090410108 @default.
• W2016242021 cites W2093666338 @default.
• W2016242021 cites W2093953040 @default.
• W2016242021 cites W2094526738 @default.
• W2016242021 cites W2096625946 @default.
• W2016242021 cites W2105117087 @default.
• W2016242021 cites W2108086513 @default.
• W2016242021 cites W2108586733 @default.
• W2016242021 cites W2111129606 @default.
• W2016242021 cites W2113846910 @default.
• W2016242021 cites W2116013738 @default.
• W2016242021 cites W2117379708 @default.
• W2016242021 cites W2121746863 @default.
• W2016242021 cites W2122653113 @default.
• W2016242021 cites W2123654285 @default.
• W2016242021 cites W2125409131 @default.
• W2016242021 cites W2134184188 @default.
• W2016242021 cites W2138558289 @default.
• W2016242021 cites W2140657592 @default.
• W2016242021 cites W2140881278 @default.
• W2016242021 cites W2141474125 @default.
• W2016242021 cites W2143565660 @default.
• W2016242021 cites W2145424103 @default.
• W2016242021 cites W2146934919 @default.
• W2016242021 cites W2152524078 @default.

• next